Orelabrutinib Clinical Trials
29 recruitingDrug
Phase 218Phase 39Not Applicable2Phase 41
Showing 1–20 of 29 trials
Recruiting
Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled9 locationsNCT07067463
Recruiting
Phase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC990 enrolled8 locationsNCT07299019
Recruiting
Phase 2
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
MALT Lymphoma
Zhejiang Cancer Hospital60 enrolled2 locationsNCT07554898
Recruiting
Phase 2
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Follicular LymphomaRelapsed and Refractory Follicular Lymphoma
Sun Yat-sen University32 enrolled3 locationsNCT04989621
Recruiting
Phase 2
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Marginal Zone Lymphoma (MZL)
Ruijin Hospital145 enrolled3 locationsNCT06793189
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07448324
Recruiting
Phase 2
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China30 enrolled14 locationsNCT07441993
Recruiting
Phase 2
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.394 enrolled2 locationsNCT07377578
Recruiting
Phase 4
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Marginal Zone Lymphoma (MZL)
Beijing Tongren Hospital88 enrolled3 locationsNCT07355699
Recruiting
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Mantle Cell Lymphoma (MCL)
Ruijin Hospital25 enrolled1 locationNCT07272499
Recruiting
Not Applicable
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)POZ
Peking University Third Hospital34 enrolled1 locationNCT07257510
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University169 enrolled1 locationNCT07208981
Recruiting
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Mantle Cell Lymphoma (MCL)
Ruijin Hospital45 enrolled1 locationNCT07199296
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 2
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Primary Central Nervous System Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University19 enrolled1 locationNCT04961515
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Marginal Zone Lymphoma (MZL)
Fei Li90 enrolled1 locationNCT06700798
Recruiting
Phase 2
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Diffuse Large B Cell Lymphoma
Affiliated Hospital of Nantong University30 enrolled2 locationsNCT06530511